# Project 003 — Final Phase 2 Release

## Status

PHASE 2 COMPLETE — PASS.

All 20 criteria frozen in the Project 003 Phase 2 protocol passed in the
successful Phase 2E final-validation execution.

## Successful execution

Execution base commit:

`9bf60ae996af7430d8dada11c9456221b0c90cc9`

Successful Phase 2E runner SHA-256:

`b7a55615a464bf536ae3c2673b4af614963f0e7f1abed6afb78a441dbaf6af35`

Success marker:

`PHASE2E_FINAL_VALIDATION_PASS`

Independent release-verification marker:

`PROJECT003_PHASE2_FINAL_RELEASE_INDEPENDENT_VERIFICATION_PASS`

## Final authoritative archive

Path:

`results/phase2e/omicsedge_phase2_final_results.tar.gz`

SHA-256:

`186cbed74fa718a728f7a24b43d58118a308165fae385eb95cc4cb4444788ca3`

Size:

`8,708,768 bytes`

The archive was independently extracted after the successful Phase 2E run.

Every artifact in its internal `checksums.sha256` manifest passed independent
verification.

The nested frozen Phase 1A, Phase 1B, Phase 2C, and Phase 2D authority
archives also reproduced their frozen SHA-256 identities.

## Final Phase 2 gate

Final verdict:

`PASS`

Validation:

`20 / 20 PASS`

Failed gates:

`0`

The final gate remained the 20 criteria originally frozen before Phase 2
source selection and computation.

## Registry generalization demonstrated

Final evidence scope includes:

- samples: HG002, HG003, HG004
- total benchmark samples: 3
- paired Phase 2 technologies: Illumina and Oxford Nanopore
- Phase 2 genomic contexts: 5
- Phase 2 represented chromosomes: 19
- Phase 2C EVENT records: 7,951
- Phase 2C OBSERVATION records: 15,902
- Phase 2D exact EVENT_VARIANT_LINK records: 7,891
- Phase 2D UNRESOLVED EVENT records: 60
- Phase 2D biological VARIANT identities touched: 2,612

The deterministic final product query returns 8 observation rows spanning
2 samples and 2 sequencing technologies while preserving the original
experiment, benchmark-run, EVENT, OBSERVATION, truth/query side, raw
comparator decision, source provenance, and biological identity method.

## P2-13 Run-1 validator correction

The first Phase 2E execution produced `STOP` because the P2-13 validator
incorrectly required the nonexistent literal:

`identity_scope == "RUN_SCOPED"`

The frozen Phase 2C implementation instead uses `identity_scope` for its
within-run derivation mechanism.

The post-Run-1 diagnostic demonstrated that all 7,951 EVENT identifiers were
unique and benchmark-run namespaced, all EVENTs referenced valid benchmark
runs, Phase 2D accounted for every EVENT exactly once, no EVENT had more than
one biological VARIANT link, and every EVENT_VARIANT_LINK preserved its
source BENCHMARK_RUN.

The validator-only correction was frozen before Run 2.

Its lock SHA-256 is:

`82f9d5bb5893931f456b778546d359061bf8bbad7169f1e78899271a68f764dd`

No scientific record, identity rule, frozen Phase 2 criterion, or verdict
semantics were changed by the correction.

Run 1 remains provenance for a validator false negative and is not the
authoritative Phase 2 result.

## Scientific boundaries

The final Phase 2 release does not:

- create a reliability score;
- create a confidence score;
- create a trust label;
- rank sequencing technologies;
- rank callers;
- generate majority-vote or forced consensus;
- infer representation equivalence;
- assign guessed VARIANT identity to unresolved EVENTs;
- perform clinical interpretation;
- infer pathogenicity.

Representation-equivalence inference remains disabled.

## Limitations

The final report inside the authoritative archive explicitly preserves:

- dataset-selection scope;
- benchmark-truth limitations;
- unresolved representation equivalence;
- the distinction between empirical evidence aggregation and biological or
  clinical truth.

## Compute

Phase 2E performed no new genomic benchmarking.

The final-validation and release-packaging stage used compact local
transformations only.

Additional paid compute for Phase 2E:

`CAD 0`
